Table 3.
Variables | Recurrence-free survival |
||
---|---|---|---|
Hazard ratio | 95% confidence interval | P-value | |
All patients | |||
Breast cancer subtype | |||
HR positive | 1.0 | ||
HER2 positive | 2.58 | 0.97–6.83 | 0.0572 |
Triple receptor negative | 2.13 | 0.83–5.48 | 0.117 |
Clinical stage at diagnosis | |||
I and II | 1.0 | ||
III | 1.02 | 0.515–2.029 | 0.95 |
Nuclear grade | |||
1 and 2 | 1.0 | ||
3 | 1.64 | 0.56–4.79 | 0.362 |
Residual cancer burden (continuous) | 1.01 | 0.99–1.02 | 0.346 |
Risk score all patients (RS-All) | 2.09 | 1.36–3.21 | 0.0008 |
Patients with HR-positive disease | |||
Clinical stage at diagnosis | |||
I and II | 1.0 | ||
III | 0.33 | 0.08–1.43 | 0.1388 |
Nuclear grade | |||
1 and 2 | 1.0 | ||
3 | 2.2 | 0.59–8.43 | 0.2405 |
Residual cancer burden (continuous) | 1.02 | 0.99–1.05 | 0.2211 |
Risk score HR positive (RS-HR) | 2.87 | 1.31–6.26 | 0.0083 |